Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956317 · ClinicalTrials.gov registry record · Phase 1
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
A Phase 1 study, sponsored by Sirnaomics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02956317 is a Phase 1 study that has completed, run by Sirnaomics. The registered enrollment target is 25 participants.
The verdict
NCT02956317, a Phase 1 study, has completed, sponsored by Sirnaomics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, within-subject placebo controlled study to evaluate the safety and efficacy of various doses of STP705 administered as intradermal Injection in subjects with hypertrophic scar. The goals are to determine the recommended Phase 2 dose, the pharmacokinetics and pharmacidynamics parameters, and conduct analysis of biomarkers common to the scar formation pathway.
Interventions
- DRUG Placebo
- DRUG STP705
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956317
The ClinicalTrials.gov registry entry for NCT02956317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02956317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956317 about?
NCT02956317 is a clinical study titled "A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar". This is a randomized, double-blind, within-subject placebo controlled study to evaluate the safety and efficacy of various doses of STP705 administered as intradermal Injection in subjects with hypertrophic scar. The goals are to determine the recommended Phase 2 dose, the pharmacokinetics and pharm...
What is the current status of trial NCT02956317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-01. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02956317?
The interventions under investigation include: Placebo (DRUG), STP705 (DRUG).
Who is sponsoring clinical trial NCT02956317?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.